CAMBRIDGE, Mass. , ROTTERDAM, Netherlands and SUZHOU, China , Aug. 28, 2024 /PRNewswire/ -- Harbour BioMed ("HBM", or the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery, development, and commercialization of novel antibody therapeutics focusing on oncology and immunology, today announced its interim results for the six months ended June 30, 2024 .
Dr. Jingsong Wang , Founder, Chairman and CEO of Harbour BioMed, commented, "In the first half of 2024, Harbour BioMed remained profitable, demonstrating the Company's remarkable resilience and adaptability in challenging market conditions. Our global operations continue to open new avenues for future growth.
Our outstanding performance has validated the feasibility of the Two-Engine strategy, driven by Harbour Therapeutics and Nona Biosciences. We are confident in our ability to enhance value creation and drive sustainable growth by fully unlocking the tremendous potential of our core innovation engine." The Company reported revenues of US$23.
7 million for the first half of 2024, achieving an overall profit of approximately US$1.4 million , with a solid cash balance exceeding US$183 million . Harbour Therapeutics: Robust Portfolio and Differentiated Pipeline The Company has a robust and diversified pipeline with potentially differentiated drug candidates in immuno-oncology and inflammatory and immunology diseases.
Key products include HBM9161, HBM4003, HBM9378 and HBM1020. The Company aims to.